These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 3103425)

  • 1. Inhibitors occur more frequently in African-American and Latino haemophiliacs.
    Aledort LM; Dimichele DM
    Haemophilia; 1998 Jan; 4(1):68. PubMed ID: 9873872
    [No Abstract]   [Full Text] [Related]  

  • 2. [Advances in Hemophilia A inhibitors].
    Wang SX; Yang RC
    Zhonghua Xue Ye Xue Za Zhi; 2017 May; 38(5):444-448. PubMed ID: 28565748
    [No Abstract]   [Full Text] [Related]  

  • 3. The prevalence of anti-factor VIII and anti-factor IX antibodies among patients with hemophilia in Rabat, Morocco: a single center experience.
    Bouyadmar M; Khorassani ME; Kababri ME; Kili A; Hessissen L
    Pan Afr Med J; 2022; 41():126. PubMed ID: 35480405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in the Treatment of Hemophilia: A Review.
    Marchesini E; Morfini M; Valentino L
    Biologics; 2021; 15():221-235. PubMed ID: 34163136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A.
    Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
    Int J Hematol; 2003 Dec; 78(5):467-74. PubMed ID: 14704043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A.
    Gilles JG; Desqueper B; Lenk H; Vermylen J; Saint-Remy JM
    J Clin Invest; 1996 Mar; 97(6):1382-8. PubMed ID: 8617869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist.
    Pascual V; Capra JD
    J Clin Invest; 1996 Mar; 97(6):1357-8. PubMed ID: 8617864
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII.
    Bray G
    Ann Hematol; 1994; 68 Suppl 3():S29-34. PubMed ID: 8180254
    [No Abstract]   [Full Text] [Related]  

  • 9. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.
    Gilles JG; Saint-Remy JM
    J Clin Invest; 1994 Oct; 94(4):1496-505. PubMed ID: 7523452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular genetic analysis of haemophilia A; characterization of six partial deletions in the factor VIII gene.
    Millar DS; Steinbrecher RA; Wieland K; Grundy CB; Martinowitz U; Krawczak M; Zoll B; Whitmore D; Stephenson J; Mibashan RS
    Hum Genet; 1990 Dec; 86(2):219-27. PubMed ID: 2125022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophilia treatment in historical perspective: a review of medical and social developments.
    Rosendaal FR; Smit C; Briët E
    Ann Hematol; 1991 Feb; 62(1):5-15. PubMed ID: 1903310
    [No Abstract]   [Full Text] [Related]  

  • 12. Factor VIII inhibitors in patients with hemophilia A.
    Oren H; Yaprak I; Irken G
    Acta Haematol; 1999; 102(1):42-6. PubMed ID: 10473887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence of factor VIII inhibitors in patients with severe hemophilia A.
    Hoyer LW
    Adv Exp Med Biol; 1995; 386():35-45. PubMed ID: 8851013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of patients with factor VIII inhibitors.
    Lusher JM
    Transfus Med Rev; 1987 Aug; 1(2):123-30. PubMed ID: 2980269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates.
    Schwarzinger I; Pabinger I; Korninger C; Haschke F; Kundi M; Niessner H; Lechner K
    Am J Hematol; 1987 Mar; 24(3):241-5. PubMed ID: 3103425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
    Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.